Standout Papers

Canagliflozin and Cardiovascular and Renal Events i... 2009 2026 2014 2020 5.2k
  1. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017)
    Bruce Neal, Vlado Perkovic et al. New England Journal of Medicine
  2. Worldwide access to treatment for end-stage kidney disease: a systematic review (2015)
    Thaminda Liyanage, Toshiharu Ninomiya et al. The Lancet
  3. Chronic kidney disease (2021)
    Kamyar Kalantar‐Zadeh, Tazeen H. Jafar et al. The Lancet
  4. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk (2018)
    Julio Rosenstock, Vlado Perkovic et al. JAMA
  5. Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes (2009)
    Toshiharu Ninomiya, Vlado Perkovic et al. Journal of the American Society of Nephrology
  6. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis (2010)
    Min Jun, Celine Foote et al. The Lancet
  7. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis (2015)
    Xinfang Xie, Emily Atkins et al. The Lancet
  8. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension (2016)
    Michael Hecht Olsen, Sonia Y. Angell et al. The Lancet
  9. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis (2019)
    Brendon L. Neuen, T. Kue Young et al. The Lancet Diabetes & Endocrinology
  10. Blood Pressure Lowering in Type 2 Diabetes (2015)
    Connor A. Emdin, Kazem Rahimi et al. JAMA
  11. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials (2018)
    Vlado Perkovic, Dick de Zeeuw et al. The Lancet Diabetes & Endocrinology
  12. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis (2016)
    Jason Wu, Celine Foote et al. The Lancet Diabetes & Endocrinology
  13. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events (2017)
    Kenneth W. Mahaffey, Bruce Neal et al. Circulation
  14. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018)
    Karin Rådholm, Gemma A. Figtree et al. Circulation
  15. Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency (2019)
    Andrew S. Levey, Ron T. Gansevoort et al. American Journal of Kidney Diseases
  16. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta‐analysis (2019)
    Tadashi Toyama, Brendon L. Neuen et al. Diabetes Obesity and Metabolism
  17. Prevalence of chronic kidney disease in Asia: a systematic review and analysis (2022)
    Thaminda Liyanage, Tadashi Toyama et al. BMJ Global Health
  18. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021)
    Ahmed M. Shaman, Stephen C. Bain et al. Circulation
  19. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease (2023)
    Peter Rossing, Florian M.M. Baeres et al. Nephrology Dialysis Transplantation
  20. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria (2023)
    Brendon L. Neuen, Hiddo J.L. Heerspink et al. Circulation
  21. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial (2024)
    Johannes F.E. Mann, Peter Rossing et al. Nature Medicine

Immediate Impact

2 from Science/Nature 132 standout
Sub-graph 1 of 13

Citing Papers

Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
2025 Standout
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
2024 Standout
56 intermediate papers

Works of Vlado Perkovic being referenced

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
2023 Standout
Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy
2022
and 44 more

Author Peers

Author Last Decade Papers Cites
Vlado Perkovic 15353 8477 7676 7799 398 29.1k
Johannes F.E. Mann 13170 8974 5887 10175 275 28.7k
Hiddo J.L. Heerspink 15519 10487 6576 6359 583 27.7k
Peter Rossing 22306 10797 7288 10480 737 39.4k
Elizabeth Selvin 11516 4733 5268 7730 507 31.6k
Mark E. Cooper 17386 12906 5789 12490 506 47.5k
Itamar Raz 14772 2875 5439 6237 370 25.1k
Luís M. Ruilope 9780 4805 4682 19422 754 29.8k
Eberhard Ritz 9208 19039 5986 13530 926 43.6k
Katherine R. Tuttle 7969 7164 3409 3204 291 18.4k
Christoph Wanner 17206 13557 11513 8088 706 44.5k

All Works

Loading papers...

Rankless by CCL
2026